Lü Lin, Zeng Han-qing, Wang Pi-long, Shen Wei, Xiang Ting-xiu, Mei Zhe-chuan
Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Clin Vaccine Immunol. 2011 Nov;18(11):1957-61. doi: 10.1128/CVI.05306-11. Epub 2011 Sep 7.
Helicobacter pylori infection is prevalent worldwide and results in chronic gastritis, which may lead to gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. We have previously reported that oral immunization with recombinant Mycobacterium smegmatis expressing the H. pylori outer membrane protein 26-kilodalton (Omp26) antigen affords therapeutic protection against H. pylori infection in mice. In the present study, we investigated the prophylactic effects of this vaccine candidate on H. pylori challenge in mice. We found that oral immunization with recombinant Mycobacterium Omp26 significantly reduced H. pylori colonization in the stomach compared to inoculation with wild-type M. smegmatis in control mice. Six of the recombinant Mycobacterium-immunized mice (60%) were completely protected from H. pylori infection. The severity of H. pylori-associated chronic gastritis assessed histologically was significantly milder in mice vaccinated with recombinant Mycobacterium than in control animals. Mice immunized with recombinant Mycobacterium showed enhanced antigen-specific lymphocyte proliferation and antibody responses. Moreover, immunization with recombinant Mycobacterium resulted in an increased expression of interleukin-2 and gamma interferon in the stomach and spleen, as determined by reverse transcription-PCR analysis. Our results collectively suggest that vaccination with recombinant Mycobacterium Omp26 confers prophylactic protection against H. pylori infection. The inhibition of H. pylori colonization is associated with the induction of antigen-specific humoral and cell-mediated immune responses.
幽门螺杆菌感染在全球范围内普遍存在，会导致慢性胃炎，而慢性胃炎可能会引发胃黏膜相关淋巴组织淋巴瘤和胃癌。我们之前曾报道，用表达幽门螺杆菌26千道尔顿外膜蛋白（Omp26）抗原的重组耻垢分枝杆菌进行口服免疫，可为小鼠提供针对幽门螺杆菌感染的治疗性保护。在本研究中，我们调查了这种候选疫苗对小鼠幽门螺杆菌攻击的预防效果。我们发现，与对照小鼠接种野生型耻垢分枝杆菌相比，用重组分枝杆菌Omp26进行口服免疫可显著减少胃中幽门螺杆菌的定植。六只接受重组分枝杆菌免疫的小鼠（60%）完全免受幽门螺杆菌感染。组织学评估显示，接种重组分枝杆菌的小鼠中幽门螺杆菌相关慢性胃炎的严重程度明显低于对照动物。用重组分枝杆菌免疫的小鼠表现出增强的抗原特异性淋巴细胞增殖和抗体反应。此外，通过逆转录聚合酶链反应分析确定，用重组分枝杆菌免疫导致胃和脾脏中白细胞介素-2和γ干扰素的表达增加。我们的结果共同表明，用重组分枝杆菌Omp26进行疫苗接种可提供针对幽门螺杆菌感染的预防性保护。幽门螺杆菌定植的抑制与抗原特异性体液免疫和细胞介导免疫反应的诱导有关。
